IUPAC Name
1-(1,2-diphenylethyl)piperidine
Current Scheduling Status
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
MDMB-4en-PINACA (chemical name: methyl-3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3-carboxamido)butanoate) is a synthetic cannabinoid. It has been identified in seized material formulated for smoking and found as white to yellow–brown powder.
WHO review history
MDMB-4en-PINACA has not been formally reviewed by WHO and is not currently under international control. Information was brought to WHO’s attention that this substance is manufactured clandestinely, poses a risk to public health and has no recognized therapeutic use.
Similarity to known substances and effects on the central nervous system
MDMB-4en-PINACA is a synthetic cannabinoid that binds to cannabinoid (CB1) receptors as a full and potent agonist. It is structurally similar to 5F-MDMB-PINACA (5F-ADB), which is controlled under Schedule II of the Convention on Psychotropic Substances of 1971. A report of an unpublished study in animals indicates that MDMB- 4en-PINACA can have the characteristic effects of CB1 agonists, such as hypothermia and lethargy. Reports on online user forums describe cannabis-like euphoria at moderate levels of intake, with dissociation described at higher doses. Both sedation and stimulation have been reported, in addition to memory loss, confusion and agitation.
Dependence potential
No studies have been reported in animals or humans on the dependence potential of MDMB-4en-PINACA. As it is a full CB1 agonist, it would be expected to produce dependence similarly to other CB1 receptor agonists.
Actual abuse and/or evidence of likelihood of abuse
No studies have been reported in animals or humans to indicate the likelihood of abuse of MDMB-4en-PINACA; however, CB1 receptor agonists have known abuse potential. A number of countries in various regions have reported use of MDMB-4en- PINACA. Its use has been associated with cases of impaired driving and death.
Therapeutic usefulness
MDMB-4en-PINACA has no known therapeutic use.
Recommendation
MDMB-4en-PINACA (chemical name: methyl-3,3-dimethyl-2-(1-(pent- 4-en-1-yl)-1H-indazole-3-carboxamido)butanoate) is a potent synthetic cannabinoid receptor agonist with a similar mechanism of action and similar effects to a number of other synthetic cannabinoids that are controlled under Schedule II of the Convention on Psychotropic Substances of 1971. Use of MDMB-4en-PINACA has been associated with severe adverse effects, including fatal intoxication and cases of impaired driving. MDMB-4en- PINACA has no therapeutic use.
Recommendation: The Committee recommended that MDMB-4en-PINACA (chemical name: methyl (S)-3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole- 3-carboxamido)butanoate) be added to Schedule II of the Convention on Psychotropic Substances of 1971.
MDMB-4en-PINACA (chemical name: methyl-3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3-carboxamido)butanoate) is a synthetic cannabinoid. It has been identified in seized material formulated for smoking and found as white to yellow–brown powder.
WHO review history
MDMB-4en-PINACA has not been formally reviewed by WHO and is not currently under international control. Information was brought to WHO’s attention that this substance is manufactured clandestinely, poses a risk to public health and has no recognized therapeutic use.
Similarity to known substances and effects on the central nervous system
MDMB-4en-PINACA is a synthetic cannabinoid that binds to cannabinoid (CB1) receptors as a full and potent agonist. It is structurally similar to 5F-MDMB-PINACA (5F-ADB), which is controlled under Schedule II of the Convention on Psychotropic Substances of 1971. A report of an unpublished study in animals indicates that MDMB- 4en-PINACA can have the characteristic effects of CB1 agonists, such as hypothermia and lethargy. Reports on online user forums describe cannabis-like euphoria at moderate levels of intake, with dissociation described at higher doses. Both sedation and stimulation have been reported, in addition to memory loss, confusion and agitation.
Dependence potential
No studies have been reported in animals or humans on the dependence potential of MDMB-4en-PINACA. As it is a full CB1 agonist, it would be expected to produce dependence similarly to other CB1 receptor agonists.
Actual abuse and/or evidence of likelihood of abuse
No studies have been reported in animals or humans to indicate the likelihood of abuse of MDMB-4en-PINACA; however, CB1 receptor agonists have known abuse potential. A number of countries in various regions have reported use of MDMB-4en- PINACA. Its use has been associated with cases of impaired driving and death.
Therapeutic usefulness
MDMB-4en-PINACA has no known therapeutic use.
Recommendation
MDMB-4en-PINACA (chemical name: methyl-3,3-dimethyl-2-(1-(pent- 4-en-1-yl)-1H-indazole-3-carboxamido)butanoate) is a potent synthetic cannabinoid receptor agonist with a similar mechanism of action and similar effects to a number of other synthetic cannabinoids that are controlled under Schedule II of the Convention on Psychotropic Substances of 1971. Use of MDMB-4en-PINACA has been associated with severe adverse effects, including fatal intoxication and cases of impaired driving. MDMB-4en- PINACA has no therapeutic use.
Recommendation: The Committee recommended that MDMB-4en-PINACA (chemical name: methyl (S)-3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole- 3-carboxamido)butanoate) be added to Schedule II of the Convention on Psychotropic Substances of 1971.
ECDD Recommendation
Inclusion in Schedule II of the 1971 Convention on Psychotropic Substances
Link to full TRS
9789240023024-eng.pdf1.84 MB
MS Questionnaire Report